Europe Injectable Drug Delivery Devices Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024
The Europe Injectable Drug Delivery Market is accounted to reach USD 265.0 billion by 2024 from USD 107.4 billion in 2016, it is growing at a CAGR of 11.9 % in the forecast period 2017 to 2024.
The major factors driving the growth of this market are the increasing use of biologics, rising prevalence of chronic diseases, increasing occurrence of needle-stick injuries, and the benefits of injections (convenience, ease of use, and reduced pain).
The key market players for Europe Injectable Drug Delivery Devices Market are listed below:
Based on type, the global injectable drug delivery market is segmented into devices and formulations.
By product, the needle free injectors are further segmented into fillable needle-free injectors and prefilled needle-free injectors.
By usability the needle free injector is segmented into disposable and reusable injectors.
By design, the auto injectors are segmented into standardized and customizable auto injectors.
On the basis of applications, the Injectable drug delivery market is segmented into hormonal disorders, oncology, autoimmune diseases, orphan diseases, and others.
Based on indications into rheumatoid arthritis, multiple sclerosis, Crohn’s disease, psoriasis and others. Hormonal disorders are further segmented into indications such as diabetes, antithrombotic therapy, reproductive health diseases, anemia, osteoporosis and others.
On the basis of usage pattern the injectable drug delivery market is segmented into curative care, immunization, and others.
Based on mode of administration the market is segmented into skin, circulatory, organs and central nervous system.
On the basis of end user the europe injectable drug delivery market is segmented into hospitals, clinics, home care settings, research laboratories and, pharma & biotech companies.
Based on geography, the Europe Injectable Drug Delivery Devices market is segmented into 11 geographical regions, such as,
The report covers the present scenario and the growth prospects of the Europe Injectable Drug Delivery Devices market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
The major factors driving the growth of this market are the increasing use of biologics, rising prevalence of chronic diseases, increasing occurrence of needle-stick injuries, and the benefits of injections (convenience, ease of use, and reduced pain).
The key market players for Europe Injectable Drug Delivery Devices Market are listed below:
- Pfizer and Baxter International, Inc.,
- Gerresheimer AG,
- Schott AG, Alkermes Plc.,
- Eli Lilly and Company,
- Sandoz,
- Terumo Corporation,
- Teva Pharmaceuticals Industries Ltd.,
- Bespak, Antares Pharma,
- Elcam Medical,
- Haselmeier, Mylan N.V.,
- Novo Nordisk,
- Owen Mumford Ltd,Sanofi,
- West Pharmaceutical Services, Inc,
- Ypsomed Holding AG.
- Type
- Application
- Usage Pattern
- Mode Administration
- End User
- Geography
Based on type, the global injectable drug delivery market is segmented into devices and formulations.
By product, the needle free injectors are further segmented into fillable needle-free injectors and prefilled needle-free injectors.
By usability the needle free injector is segmented into disposable and reusable injectors.
By design, the auto injectors are segmented into standardized and customizable auto injectors.
On the basis of applications, the Injectable drug delivery market is segmented into hormonal disorders, oncology, autoimmune diseases, orphan diseases, and others.
Based on indications into rheumatoid arthritis, multiple sclerosis, Crohn’s disease, psoriasis and others. Hormonal disorders are further segmented into indications such as diabetes, antithrombotic therapy, reproductive health diseases, anemia, osteoporosis and others.
On the basis of usage pattern the injectable drug delivery market is segmented into curative care, immunization, and others.
Based on mode of administration the market is segmented into skin, circulatory, organs and central nervous system.
On the basis of end user the europe injectable drug delivery market is segmented into hospitals, clinics, home care settings, research laboratories and, pharma & biotech companies.
Based on geography, the Europe Injectable Drug Delivery Devices market is segmented into 11 geographical regions, such as,
- France,
- U.K.,
- Germany
- Italy.
The report covers the present scenario and the growth prospects of the Europe Injectable Drug Delivery Devices market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of the web conferencing and unified communication and collaboration (UC&C) and video conferencing, secondary resources and doing in-depth company share analysis of major 10 players in the market.
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
1 INTRODUCTION
1.1. OVERVIEW OF THE EUROPE BODY COMPOSITION ANALYZER MARKET
1.2. CURRENCY AND PRICING
1.3. LIMITATION
1.4. MARKETS COVERED
2 MARKET SEGMENTATION
2.1. KEY TAKEAWAYS
2.2. ARRIVING AT THE EUROPE INJECTABLE DRUG DELIVERY MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 MARKET TIME LINE
2.2.4 MARKET GUIDE
2.2.5 COMPANY POSITIONING GRID
2.2.6 COMAPANY MARKET SHARE ANALYSIS
2.2.7 MULTIVARIATE MODELLING
2.2.8 STANDARDS OF MEASUREMENT
2.2.9 TOP TO BOTTOM ANALYSIS
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3. EUROPE INJECTABLE DRUG DELIVERY MARKET: RESEARCH SNAPSHOT
2.4. ASSUMPTIONS
3 MARKET OVERVIEW
3.1. DRIVERS
3.2. RESTRAINTS
3.3. OPPORTUNITIES
3.4. CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1. VENDOR POSITIONING GRID AND INVESTMENT OPPORTUNITIES
5.2. TECHNOLOLGICAL ADVANCEMENTS
5.3. INSIGHTS ON TECHNOLOGICAL DEVELOPMENTS IN THE EUROPE INJECTABLE DRUG DELIVERY MARKET
5.4. MARKET REGULATORY SCENARIO BY COUNTRY
5.5. INTERVIEW KEY INSIGHTS
6 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY TYPE
7 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY PRODUCT
8 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION
9 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY END USER
10 EUROPE INJECTABLE DRUG DELIVERY MARKET: GEOGRAPHY
11 EUROPE INJECTABLE DRUG DELIVERY MARKET, COMPANY PROFILES
11.1 PFIZER AND BAXTER INTERNATIONAL, INC.
11.2 GERRESHEIMER AG
11.3 SCHOTT AG, ALKERMES PLC.
11.4 ELI LILLY AND COMPANY
11.5 SANDOZ
11.6 COMPANY A
11.7 COMPANY B
11.8 COMPANY C
11.9 COMPANY D
11.10 COMPANY E
11.11 COMPANY F
11.12 COMPANY G
11.13 COMPANY H
11.14 COMPANY I
11.15 COMPANY J
11.16 COMPANY K
11.17 COMPANY M
11.18 COMPANY N
11.19 COMPANY O
12 APPENDIX
13 ABOUT DATA BRIDGE MARKET RESEARCH
1.1. OVERVIEW OF THE EUROPE BODY COMPOSITION ANALYZER MARKET
1.2. CURRENCY AND PRICING
1.3. LIMITATION
1.4. MARKETS COVERED
2 MARKET SEGMENTATION
2.1. KEY TAKEAWAYS
2.2. ARRIVING AT THE EUROPE INJECTABLE DRUG DELIVERY MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 MARKET TIME LINE
2.2.4 MARKET GUIDE
2.2.5 COMPANY POSITIONING GRID
2.2.6 COMAPANY MARKET SHARE ANALYSIS
2.2.7 MULTIVARIATE MODELLING
2.2.8 STANDARDS OF MEASUREMENT
2.2.9 TOP TO BOTTOM ANALYSIS
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3. EUROPE INJECTABLE DRUG DELIVERY MARKET: RESEARCH SNAPSHOT
2.4. ASSUMPTIONS
3 MARKET OVERVIEW
3.1. DRIVERS
3.2. RESTRAINTS
3.3. OPPORTUNITIES
3.4. CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1. VENDOR POSITIONING GRID AND INVESTMENT OPPORTUNITIES
5.2. TECHNOLOLGICAL ADVANCEMENTS
5.3. INSIGHTS ON TECHNOLOGICAL DEVELOPMENTS IN THE EUROPE INJECTABLE DRUG DELIVERY MARKET
5.4. MARKET REGULATORY SCENARIO BY COUNTRY
5.5. INTERVIEW KEY INSIGHTS
6 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY TYPE
7 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY PRODUCT
8 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY APPLICATION
9 EUROPE INJECTABLE DRUG DELIVERY MARKET, BY END USER
10 EUROPE INJECTABLE DRUG DELIVERY MARKET: GEOGRAPHY
11 EUROPE INJECTABLE DRUG DELIVERY MARKET, COMPANY PROFILES
11.1 PFIZER AND BAXTER INTERNATIONAL, INC.
11.2 GERRESHEIMER AG
11.3 SCHOTT AG, ALKERMES PLC.
11.4 ELI LILLY AND COMPANY
11.5 SANDOZ
11.6 COMPANY A
11.7 COMPANY B
11.8 COMPANY C
11.9 COMPANY D
11.10 COMPANY E
11.11 COMPANY F
11.12 COMPANY G
11.13 COMPANY H
11.14 COMPANY I
11.15 COMPANY J
11.16 COMPANY K
11.17 COMPANY M
11.18 COMPANY N
11.19 COMPANY O
12 APPENDIX
13 ABOUT DATA BRIDGE MARKET RESEARCH
